Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Change in Accured Expenses (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Change in Accured Expenses for 16 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 2580.43% to $8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.7 million through Dec 2025, up 776.77% year-over-year, with the annual reading at $6.7 million for FY2025, 776.77% up from the prior year.
  • Change in Accured Expenses hit $8.0 million in Q4 2025 for Cumberland Pharmaceuticals, up from $684224.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $8.0 million in Q4 2025 to a low of -$3.3 million in Q4 2023.
  • Historically, Change in Accured Expenses has averaged $904548.0 across 5 years, with a median of $166060.0 in 2021.
  • Biggest five-year swings in Change in Accured Expenses: surged 2957.92% in 2022 and later crashed 185.82% in 2024.
  • Year by year, Change in Accured Expenses stood at $2.1 million in 2021, then skyrocketed by 172.09% to $5.8 million in 2022, then plummeted by 157.46% to -$3.3 million in 2023, then skyrocketed by 90.2% to -$324294.0 in 2024, then soared by 2580.43% to $8.0 million in 2025.
  • Business Quant data shows Change in Accured Expenses for CPIX at $8.0 million in Q4 2025, $684224.0 in Q3 2025, and -$1.4 million in Q2 2025.